We are a biopharmaceutical company focused on the discovery, development and commercialization of polymer-based drugs to treat conditions that are often overlooked and undertreated, but that can have a serious impact on patients’ lives and even be life-threatening. On October 21, 2015, the U.S. Food and Drug Administration, or FDA, approved our first drug, Veltassa® (patiromer) for oral suspension, or Veltassa, for the treatment of hyperkalemia. Hyperkalemia is a life threatening condition defined as abnormally elevated levels of potassium in the blood. Veltassa is a non-absorbed, high capacity potassium binding polymer with a well-established mode of action. In our clinical trials, Veltassa met its efficacy endpoints, reducing serum potassium, or potassium in the blood, to target levels and sustaining potassium in the desired range and was well tolerated for up to 52 weeks.
Company profile
Ticker
RLYP
Exchange
Employees
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
260893742
Latest filings (excl ownership)
CT ORDER
Confidential treatment order
13 Aug 19
CT ORDER
Confidential treatment order
13 Aug 19
CT ORDER
Confidential treatment order
17 Sep 18
CT ORDER
Confidential treatment order
20 Oct 16
CT ORDER
Confidential treatment order
19 Sep 16
15-12B
Securities registration termination
12 Sep 16
EFFECT
Notice of effectiveness
9 Sep 16
EFFECT
Notice of effectiveness
9 Sep 16
POS AM
Prospectus update (post-effective amendment)
6 Sep 16
POS AM
Prospectus update (post-effective amendment)
6 Sep 16
Latest ownership filings
SC 13G/A
Relypsa Inc
14 Feb 17
SC 13G/A
Relypsa Inc
14 Feb 17
SC 13G/A
Beneficial ownership report (amended)
7 Oct 16
4
Mary Corbett
2 Sep 16
4
PAUL J HASTINGS
2 Sep 16
4
DANIEL K SPIEGELMAN
2 Sep 16
4
Monte Montgomery
2 Sep 16
4
Stephen D Harrison
2 Sep 16
4
KRISTINE M BALL
2 Sep 16
4
J. Scott Garland
2 Sep 16
Institutional ownership, Q3 2019
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|